According to the Zhixun Finance and Economics app, on Wednesday, stocks related to weight loss drugs fell. At the time of publication, Novo Nordisk (NVO.US) fell more than 4%, Eli Lilly and Co (LLY.US) fell 1.6%, and Pfizer (PFE.US) fell 0.34%. An analysis by doctors at Massachusetts Eye and Ear, a hospital affiliated with Harvard University, showed that Novo Nordisk's best-selling weight loss drugs Ozempic and Wegovy appear to be associated with an increased risk of rare vision loss. Research on medical records shows that compared to those who use other brands of weight loss drugs, patients who use Novo Nordisk's weight loss drugs to lose weight are seven times more likely to develop non-arteritic anterior ischemic optic neuropathy (NAION).
美股异动 | 减肥药概念相关股下跌 诺和诺德(NVO.US)跌超4%
US stocks fluctuate | Shares related to weight loss drugs decline and Novo Nordisk (NVO.US) falls by more than 4%.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.